Cover Image

Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register

Aims: To explore the patterns of use of oral glucose-lowering drugs (OGLDs) in Asian patients with type 2 diabetes (T2D), focusing on sulphonylureas (SUs), and to describe patient profiles according to treatment regimen. Methods: We conducted a cross-sectional analysis of data from adults with T2D f...

Full description

Saved in:
Bibliographic Details
Main Authors: Lim, Lee-Ling, Lau, Eric S. H., Cheung, Johnny T. K., Chan, Siew Pheng, Ji, Linong, Lim, Soo, Sirinvaravong, Sirinart, Unnikrishnan, A. G., Luk, Andrea O. Y., Cortese, Viviana, Durocher, Alexandra, Chan, Juliana C. N.
Format: Article
Published: Wiley 2023
Subjects:
QD Chemistry
RC Internal medicine
Online Access:http://eprints.um.edu.my/39428/
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.um.eprints.39428
record_format eprints
spelling my.um.eprints.394282023-11-29T03:40:04Z http://eprints.um.edu.my/39428/ Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register Lim, Lee-Ling Lau, Eric S. H. Cheung, Johnny T. K. Chan, Siew Pheng Ji, Linong Lim, Soo Sirinvaravong, Sirinart Unnikrishnan, A. G. Luk, Andrea O. Y. Cortese, Viviana Durocher, Alexandra Chan, Juliana C. N. QD Chemistry RC Internal medicine Aims: To explore the patterns of use of oral glucose-lowering drugs (OGLDs) in Asian patients with type 2 diabetes (T2D), focusing on sulphonylureas (SUs), and to describe patient profiles according to treatment regimen. Methods: We conducted a cross-sectional analysis of data from adults with T2D from 11 Asian countries/regions with structured assessment enrolled in the prospective Joint Asia Diabetes Evaluation (JADE) register between November 2007 and December 2019. Patients receiving insulin and/or injectable glucagon-like peptide-1 receptor agonists were excluded. Results: Amongst 62 512 patients (mean +/- standard deviation age: 57.3 +/- 11.8 years; 53.6% men), 54 783 (87.6%) were treated with OGLDs at enrolment. Most received one (37.5%) or two (44.2%) OGLDs. In the entire cohort, 59.4% of treated patients received SU-based therapy with variations amongst countries/regions. Overall, 79.5% of SU regimens were based on SUs plus metformin, and 22.1% on SUs plus dipeptidyl peptidase-4 inhibitors. Among SU users, gliclazide was most commonly prescribed (46.7%), followed by glimepiride (40.0%) and glibenclamide (8.1%). More gliclazide users entered the cohort with glycated haemoglobin levels <53 mmol/mol (7%) than non-gliclazide SU users (odds ratio OR] 1.09, 95% CI 1.02-1.17), with less frequent self-reported hypoglycaemia in the 3 months before registration (OR 0.81, 95% CI 0.72-0.92; adjusted for sociodemographic factors, cardiometabolic risk factors, complications, use of other OGLDs, country/region and year of registration). Conclusion: In Asia, SUs are a popular OGLD class, often combined with metformin. Good glycaemic control and safety profiles associated with the use of SUs, including gliclazide, support their position as a key treatment option in patients with T2D. Wiley 2023-01 Article PeerReviewed Lim, Lee-Ling and Lau, Eric S. H. and Cheung, Johnny T. K. and Chan, Siew Pheng and Ji, Linong and Lim, Soo and Sirinvaravong, Sirinart and Unnikrishnan, A. G. and Luk, Andrea O. Y. and Cortese, Viviana and Durocher, Alexandra and Chan, Juliana C. N. (2023) Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register. Diabetes Obesity & Metabolism, 25 (1). pp. 208-221. ISSN 1462-8902, DOI https://doi.org/10.1111/dom.14865 <https://doi.org/10.1111/dom.14865>. 10.1111/dom.14865
institution Universiti Malaya
building UM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Malaya
content_source UM Research Repository
url_provider http://eprints.um.edu.my/
topic QD Chemistry
RC Internal medicine
spellingShingle QD Chemistry
RC Internal medicine
Lim, Lee-Ling
Lau, Eric S. H.
Cheung, Johnny T. K.
Chan, Siew Pheng
Ji, Linong
Lim, Soo
Sirinvaravong, Sirinart
Unnikrishnan, A. G.
Luk, Andrea O. Y.
Cortese, Viviana
Durocher, Alexandra
Chan, Juliana C. N.
Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register
description Aims: To explore the patterns of use of oral glucose-lowering drugs (OGLDs) in Asian patients with type 2 diabetes (T2D), focusing on sulphonylureas (SUs), and to describe patient profiles according to treatment regimen. Methods: We conducted a cross-sectional analysis of data from adults with T2D from 11 Asian countries/regions with structured assessment enrolled in the prospective Joint Asia Diabetes Evaluation (JADE) register between November 2007 and December 2019. Patients receiving insulin and/or injectable glucagon-like peptide-1 receptor agonists were excluded. Results: Amongst 62 512 patients (mean +/- standard deviation age: 57.3 +/- 11.8 years; 53.6% men), 54 783 (87.6%) were treated with OGLDs at enrolment. Most received one (37.5%) or two (44.2%) OGLDs. In the entire cohort, 59.4% of treated patients received SU-based therapy with variations amongst countries/regions. Overall, 79.5% of SU regimens were based on SUs plus metformin, and 22.1% on SUs plus dipeptidyl peptidase-4 inhibitors. Among SU users, gliclazide was most commonly prescribed (46.7%), followed by glimepiride (40.0%) and glibenclamide (8.1%). More gliclazide users entered the cohort with glycated haemoglobin levels <53 mmol/mol (7%) than non-gliclazide SU users (odds ratio OR] 1.09, 95% CI 1.02-1.17), with less frequent self-reported hypoglycaemia in the 3 months before registration (OR 0.81, 95% CI 0.72-0.92; adjusted for sociodemographic factors, cardiometabolic risk factors, complications, use of other OGLDs, country/region and year of registration). Conclusion: In Asia, SUs are a popular OGLD class, often combined with metformin. Good glycaemic control and safety profiles associated with the use of SUs, including gliclazide, support their position as a key treatment option in patients with T2D.
format Article
author Lim, Lee-Ling
Lau, Eric S. H.
Cheung, Johnny T. K.
Chan, Siew Pheng
Ji, Linong
Lim, Soo
Sirinvaravong, Sirinart
Unnikrishnan, A. G.
Luk, Andrea O. Y.
Cortese, Viviana
Durocher, Alexandra
Chan, Juliana C. N.
author_facet Lim, Lee-Ling
Lau, Eric S. H.
Cheung, Johnny T. K.
Chan, Siew Pheng
Ji, Linong
Lim, Soo
Sirinvaravong, Sirinart
Unnikrishnan, A. G.
Luk, Andrea O. Y.
Cortese, Viviana
Durocher, Alexandra
Chan, Juliana C. N.
author_sort Lim, Lee-Ling
title Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register
title_short Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register
title_full Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register
title_fullStr Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register
title_full_unstemmed Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register
title_sort real-world usage of sulphonylureas in asian patients with type 2 diabetes using the joint asia diabetes evaluation (jade) register
publisher Wiley
publishDate 2023
url http://eprints.um.edu.my/39428/
_version_ 1783876690145968128
score 13.211869

Similar Items